[1] ZHANG L, WANG F, WANG L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey[J]. Lancet,2012,379(9818):815-822. doi:  10.1016/S0140-6736(12)60033-6
[2] 李小莉, 赵波, 陈文慧, 等. 贝前列素钠联合羟苯磺酸钙治疗慢性肾小球肾炎疗效观察[J]. 疑难病杂志, 2016, 15(6):595-597,601. doi:  10.3969/j.issn.1671-6450.2016.06.012
[3]

NODA M, SHIBOUTA Y, INADA Y, et al. Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist[J]. Biochem Pharmacol,1993,46(2):311-318. doi:  10.1016/0006-2952(93)90420-2
[4] 曹艳, 运乃茹, 邹爱英. 雷公藤多苷片致不良反应的meta分析[J]. 中国药房, 2018, 29(1):125-130.
[5] 吴炜飞, 程志群, 施向东. 雷公藤多苷联合缬沙坦治疗慢性肾小球肾炎合并高血压患者的临床疗效及对炎症因子的影响[J]. 中国生化药物杂志, 2016, 36(8):101-104.
[6] 华斐. 雷公藤多甙片对慢性肾小球肾炎患者血清IL-6 、IL-8及T细胞亚群的影响[J]. 国际泌尿系统杂志, 2019, 39(6):1077-1080. doi:  10.3760/cma.j.issn.1673-4416.2019.06.032
[7]

BERTHIER CC, KRETZLER M, DAVIDSON A. A systems approach to renal inflammation in SLE[J]. Clin Immunol,2017,185:109-118. doi:  10.1016/j.clim.2016.08.015
[8]

SETHI S, FERVENZA FC. Standardized classification and reporting of glomerulonephritis[J]. Nephrol Dial Transplant,2019,34(2):193-199. doi:  10.1093/ndt/gfy220
[9] 巩昭勇, 黄芳, 薛丕良, 等. 活血益肾汤联合氯沙坦钾治疗慢性肾小球肾炎疗效及对血脂和炎症反应的影响[J]. 现代中西医结合杂志, 2019, 28(23):2587-2589. doi:  10.3969/j.issn.1008-8849.2019.23.021
[10] 毛娅妮, 田少江. 补肾清利活血汤联合奥美沙坦酯治疗慢性肾小球肾炎疗效观察[J]. 现代中西医结合杂志, 2017, 26(10):1111-1113. doi:  10.3969/j.issn.1008-8849.2017.10.031
[11]

ZHOU A, YU L, LI J, et al. Renal protective effects of blocking the intrarenal renin-angiotensin system: angiotensin II type I receptor antagonist compared with angiotensin-converting enzyme inhibitor[J]. Hypertens Res,2000,23(4):391-397. doi:  10.1291/hypres.23.391
[12]

URATA H, KINOSHITA A, PEREZ D M, et al. Cloning of the gene and cDNA for human heart chymase[J]. J Biol Chem,1991,266(26):17173-17179. doi:  10.1016/S0021-9258(19)47355-9
[13] 涂晓, 杨梦蝶, 李亚妤, 等. 昆仙胶囊与雷公藤多苷片治疗慢性肾脏病的疗效及安全性比较[J]. 浙江中医药大学学报, 2021, 45(6):582-587,602.
[14]

REMUZZI A, PERICO N, SANGALLI F, et al. ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy[J]. Am J Physiol,1999,276(3):F457-F466.
[15]

MACKINNON M, SHURRAW S, AKBARI A, et al. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data[J]. Am J Kidney Dis,2006,48(1):8-20. doi:  10.1053/j.ajkd.2006.04.077
[16]

ITO K, IMANISHI M, KITO G. Comparison of the hypotensive effects of TCV-116 and losartan in chronic renal hypertensive dogs[EB/OL]. 1996
[17]

NODA M, MATSUO T, FUKUDA R, et al. Effect of candesartan cilexetil (TCV-116) in rats with chronic renal failure[J]. Kidney Int,1999,56(3):898-909. doi:  10.1046/j.1523-1755.1999.00614.x
[18]

KUROKAWA K, ABE K, SARUTA T, et al. Antiproteinuric effect of candesartan cilexetil in patients with chronic glomerulonephritis[J]. J Renin Angiotensin Aldosterone Syst,2002,3(3):167-175. doi:  10.3317/jraas.2002.037
[19] 邓晓蔚, 熊有明, 张维, 等. 昆仙胶囊联合百令胶囊治疗慢性肾小球肾炎临床研究[J]. 中国药业, 2019, 28(9):53-55. doi:  10.3969/j.issn.1006-4931.2019.09.015
[20]

TANG Y, ZHANG Y, LI L, et al. Kunxian capsule for rheumatoid arthritis: inhibition of inflammatory network and reducing adverse reactions through drug matching[J]. Front Pharmacol,2020,11:485. doi:  10.3389/fphar.2020.00485
[21] 张宁, 易无庸. 昆仙胶囊临床应用进展[J]. 中医临床研究, 2014, 6(7):147-148. doi:  10.3969/j.issn.1674-7860.2014.07.083
[22] 张楠, 郭晓琴, 田云凤, 等. 昆仙胶囊对慢性肾小球肾炎的临床疗效观察[J]. 中国中西医结合肾病杂志, 2020, 21(12):1096-1097. doi:  10.3969/j.issn.1009-587X.2020.12.020